Hepagam B (hepatitis B immune globulin/maltose)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Hepatitis B immune globulin (HBIG) is a specific immune globulin (hyperimmune globulin). HBIG contains antibody to hepatitis B surface antigen (anti-HBs) prepared from plasma of donors with high titers of anti-HBs and is used to provide temporary passive immunity to hepatitis B virus (HBV).
Hepatitis B immune globulin (HBIG) is used to provide passive immunity to hepatitis B virus (HBV) infection for prevention of perinatal HBV infection in neonates born to hepatitis B surface antigen-positive (HBsAg-positive) mothers, for postexposure prophylaxis in susceptible individuals exposed to HBV or HBsAg-positive materials (e.g., blood, plasma, serum), and for prevention of HBV recurrence in liver transplant recipients who are HBsAg-positive.
Generic name: hepatitis B immune globulin/maltose
Pronunciation: (hep-a-TYE-tis bee i-MYUN-GLOB-yoo-lin)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Hepagam B
Indications
The following indications are listed for Hepagam B:
- Hepatitis B Prevention
Also known as: Hbv Infection Prophylaxis, Hepatitis B Prophylaxis.
Dosing
No dosing information is available for this tab.
Hepatitis B immune globulin (HBIG) is administered by IM injection for prevention of perinatal hepatitis B virus (HBV) infection or for postexposure prophylaxis of HBV infection. HBIG is administered by IV infusion for prevention of HBV recurrence in liver transplant recipients
Prior to administration, HBIG should be inspected visually for particulate matter and discoloration. HBIG should be administered undiluted and should not be mixed with any other drug or solution.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Because of the potential risks to the neonate from exposure to HBV infection, pregnancy and lactation are not considered a contraindications to the use of HBIG when clearly needed. Animal reproduction studies have not been performed with HBIG and it is not known whether HBIG can cause fetal harm when administered to pregnant women. The manufacturers state that HBIG should be given to pregnant women only when clearly needed. The ACIP states there are no known risks associated with use of immune globulins for passive immunization in pregnant women.
Information on the distribution of HBIG into milk is not available; it is not known if transmission of HBIG to a nursing infant presents any unusual risk. HBIG should be administered with caution to nursing women.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.